Ablative Solutions says it’s pulled in an $8 million funding round for its perivascular renal denervation technology for treating high blood pressure.
Ablative Solutions, which is developing perivascular renal denervation technology for treating high blood pressure, raised an $8.0 million funding round, according to a regulatory filing.
Menlo Park, Calif.-based Ablative Solutions said 98 unnamed investors participated in the funding round, which consisted of debt, options and warrants.
The medical device company reported raising $1.1 million last April and $2.7 million in August. At the time Ablative said it was hoping for a total raise of $5 million, but amended that to $8.0 million in its most recent filing.
Unlike other renal denervation technologies, which use radiofrequency energy to deaden the nerves lining the renal arteries, delivered through the artery walls, the Ablative Solutions approach delivers the energy directly to the nerves themselves, according to its website.
Founded in 2011, Ablative Solutions raised a $5.3 million Series A round last year.
TROUT CREEK VENTURes
A regional co-investment fund specializing in angel and early stage private equity.